A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT07032688
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 59 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-3167 Injection — DRUG
    SHR-3167 injection.
  • Insulin Degludec Injection — DRUG
    Insulin Degludec injection.

Study Details

The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.

Key Dates

Start date
Aug 11, 2025
Status verified
Apr 2026
Primary completion
Mar 31, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
55 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-3167 Group

Primary Outcome Measure

Area under the SHR-3167 concentration-time curve (AUC SHR-3167, tau, ss). [ Time Frame: From 0 to 168 hours after SHR-3167 administration. ]

Central Contacts

Related Studies